{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T10:05:29Z","timestamp":1794391529612,"version":"4.9.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["2015-703549"],"award-info":[{"award-number":["2015-703549"]}],"id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11060-022-04109-1","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T14:02:48Z","timestamp":1659794568000},"page":"665-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy"],"prefix":"10.1007","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4961-237X","authenticated-orcid":false,"given":"Seth A.","family":"Climans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren P.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Grunfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"4109_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"4109_CR2","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1200\/JCO.20.5.1375","volume":"20","author":"R Stupp","year":"2002","unstructured":"Stupp R, Dietrich PY, Kraljevic SO et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375\u20131382. https:\/\/doi.org\/10.1200\/JCO.20.5.1375","journal-title":"J Clin Oncol"},{"key":"4109_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac072","author":"SA Climans","year":"2022","unstructured":"Climans SA, Grunfeld E, Mason WP, Chan KKW (2022) Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noac072","journal-title":"Neuro Oncol"},{"key":"4109_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","volume":"22","author":"YB Su","year":"2004","unstructured":"Su YB, Sohn S, Krown SE et al (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610\u2013616. https:\/\/doi.org\/10.1200\/JCO.2004.07.060","journal-title":"J Clin Oncol"},{"key":"4109_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/07357900701206380","volume":"25","author":"AB Schwarzberg","year":"2007","unstructured":"Schwarzberg AB, Stover EH, Sengupta T et al (2007) Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest 25:249\u2013255. https:\/\/doi.org\/10.1080\/07357900701206380","journal-title":"Cancer Invest"},{"key":"4109_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4065\/71.1.5","volume":"71","author":"SH Yale","year":"1996","unstructured":"Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 71:5\u201313. https:\/\/doi.org\/10.4065\/71.1.5","journal-title":"Mayo Clin Proc"},{"key":"4109_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.critrevonc.2012.08.002","volume":"85","author":"FY De Vos","year":"2013","unstructured":"De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, van Herpen CM (2013) Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit Rev Oncol Hematol 85:373\u2013382. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.08.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"4109_CR8","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","volume":"92","author":"J Huang","year":"2015","unstructured":"Huang J, DeWees TA, Badiyan SN et al (2015) Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys 92:1000\u20131007. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4109_CR9","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","volume":"17","author":"SA Grossman","year":"2011","unstructured":"Grossman SA, Ye X, Lesser G et al (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473\u20135480. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0774","journal-title":"Clin Cancer Res"},{"key":"4109_CR10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/jjco\/hys058","volume":"42","author":"H Hayashi","year":"2012","unstructured":"Hayashi H, Saito Y, Kokuho N et al (2012) Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma. Jpn J Clin Oncol 42:632\u2013636. https:\/\/doi.org\/10.1093\/jjco\/hys058","journal-title":"Jpn J Clin Oncol"},{"key":"4109_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/ncponc0514","volume":"3","author":"V Ganiere","year":"2006","unstructured":"Ganiere V, Christen G, Bally F et al (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi\u2019s sarcoma after temozolomide. Nat Clin Pract Oncol 3:339\u2013343. https:\/\/doi.org\/10.1038\/ncponc0514","journal-title":"Nat Clin Pract Oncol"},{"key":"4109_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.clon.2007.06.003","volume":"19","author":"SKT Yu","year":"2007","unstructured":"Yu SKT, Chalmers AJ (2007) Patients receiving standard-dose temozolomide therapy are at risk of pneumocystis carinii pneumonia. Clin Oncol 19:631\u2013632. https:\/\/doi.org\/10.1016\/j.clon.2007.06.003","journal-title":"Clin Oncol"},{"key":"4109_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-008-9593-6","volume":"89","author":"AE Sijben","year":"2008","unstructured":"Sijben AE, McIntyre JB, Rold\u00e1n GB et al (2008) Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 89:97\u2013103. https:\/\/doi.org\/10.1007\/s11060-008-9593-6","journal-title":"J Neurooncol"},{"key":"4109_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11060-011-0643-0","volume":"106","author":"N Malkoun","year":"2012","unstructured":"Malkoun N, Chargari C, Forest F et al (2012) Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol 106:127\u2013133. https:\/\/doi.org\/10.1007\/s11060-011-0643-0","journal-title":"J Neurooncol"},{"key":"4109_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3109\/00365540903321606","volume":"42","author":"EE Douzinas","year":"2010","unstructured":"Douzinas EE, Flevari K, Andrianakis I, Betrosian AP (2010) Oral atovaquone for the treatment of severe Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency. Scand J Infect Dis 42:76\u201378. https:\/\/doi.org\/10.3109\/00365540903321606","journal-title":"Scand J Infect Dis"},{"key":"4109_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/cns.14.24","volume":"3","author":"AJ Neuwelt","year":"2014","unstructured":"Neuwelt AJ, Nguyen TM, Fu R et al (2014) Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. CNS Oncol 3:267\u2013273. https:\/\/doi.org\/10.2217\/cns.14.24","journal-title":"CNS Oncol"},{"key":"4109_CR17","unstructured":"Juurlink D, Preyra C, Croxford R, et al (2006) Canadian institute for health information discharge abstract database: a validation study. https:\/\/www.ices.on.ca\/Publications\/Atlases-and-Reports\/2006\/Canadian-Institute-for-Health-Information. Accessed 5 Aug 2022"},{"key":"4109_CR18","volume-title":"The ICES practice atlas: patterns of health care in Ontario","author":"V Goel","year":"1996","unstructured":"Goel V, The ICES practice atlas: patterns of health care in Ontario (1996) The ICES practice atlas: patterns of health care in Ontario. Canadian Medical Association, Ottawa"},{"key":"4109_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052\u20131059. https:\/\/doi.org\/10.4065\/82.9.1052","journal-title":"Mayo Clin Proc"},{"key":"4109_CR20","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2014","unstructured":"R Core Team (2014) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria"},{"key":"4109_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JOP.18.00366","volume":"14","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Flowers CR (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary. J Oncol Pract 14:692\u2013695. https:\/\/doi.org\/10.1200\/JOP.18.00366","journal-title":"J Oncol Pract"},{"key":"4109_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn474","author":"R Stupp","year":"2008","unstructured":"Stupp R, Hottinger AF, van den Bent MJ et al (2008) Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdn474","journal-title":"Ann Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04109-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04109-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04109-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T08:14:18Z","timestamp":1663229658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04109-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4109"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04109-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that we have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Research Ethics Board at Sunnybrook Health Sciences Centre confirmed that this project was exempt from review under Sect.\u00a045 of Ontario\u2019s Personal Health Information Protection Act. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"ICES is an independent, non-profit research institute whose legal status under Ontario\u2019s health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}